|
|
|
06.08.26 - 14:36
|
ROUNDUP: Zoetis Slashes FY26 Outlook (AFX)
|
|
|
WASHINGTON (dpa-AFX) - While reporting financial results for the second quarter on Thursday, animal health company Zoetis, Inc. (ZTS) slashed its earnings, adjusted earnings and revenue guidance f......
|
|
|
06.08.26 - 14:12
|
Zoetis Inc. Q2 Sales Decline (AFX)
|
|
|
WASHINGTON (dpa-AFX) - Zoetis Inc. (ZTS) announced a profit for second quarter of $691 millionThe company's earnings totaled $691 million, or $1.65 per share. This compares with $726 million, or $......
|
|
|
|
|
06.08.26 - 13:06
|
Zoetis Appoints Jay Saccaro as Chief Financial Officer and Chief Operating Officer (Business Wire)
|
|
|
Saccaro's Appointment is Effective August 17, 2026; Wetteny Joseph to Serve as a Special Advisor to the CEO on Financial Matters Until Early 2027PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE: ZTS) today announced the appointment of James (Jay) Saccaro as Executive Vice President, Chief Financial Officer and Chief Operating Officer, effective August 17, 2026. In this newly created role, Mr. Saccaro will lead Zoetis' global finance function, shaping capital allocation, financial strategy, reporting and controls, and investor engagement and oversee Global Manufacturing and Supply to drive operational execution and performance. With Mr. Saccaro's appointment, Wetteny Joseph will transition to an advisory role effective August 17, 2026. Mr. Joseph has agreed to remain with the company as a Special Advisor to the CEO on financial matters until early 2027 to facilitate a smooth transition.
Mr. Saccaro joins Zoetis with extensive executive leadership experience at large-scale life sciences companies. He...
|
|
|
06.08.26 - 13:06
|
Zoetis Announces Second Quarter 2026 Results (Business Wire)
|
|
|
Revenue Flat at $2.5 Billion and Net Income of $691 Million, or $1.65 per Diluted Share, Decreasing 5% and Increasing 1%, Respectively, on a Reported Basis
Adjusted Net Income of $781 Million, or Adjusted Diluted EPS of $1.87
Revenue and Adjusted Net Income Declined 1% and 2%, Respectively, on an Organic Operational Basis
Revises Full Year 2026 Revenue Guidance to $9.120 - $9.320 Billion to Organic Operational Revenue Growth of (3)% to (1)%
Revises Full Year 2026 Adjusted Net Income Guidance to Organic Operational Growth of (9)% to (5)%
Revises Guidance for Adjusted Diluted EPS to $6.15 - $6.25
PARSIPPANY, N.J.--(BUSINESS WIRE)--$ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS), the world's leading animal health company, today reported its financial results for the second quarter of 2026.
The company reported revenue of $2.5 billion for the second quarter of 2026, flat compared with the second quarter of 2025, decreasing 1% on an organic operational1 basis. Net income for the second quarter of 2026 was $691 mil...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
22.07.26 - 13:36
|
Zoetis Launches Portela® (relfovetmab) in Canada and the European Union (Business Wire)
|
|
|
First long-acting anti-NGF monoclonal antibody therapy for cats offers three months of osteoarthritis pain relief with a single injectionPARSIPPANY, N.J.--(BUSINESS WIRE)--$ZTS #animalhealth--Zoetis Inc. (NYSE: ZTS) today announced the commercial launch of Portela® (relfovetmab) in Canada and the European Union (EU) member states. Portela is the first long-acting anti-nerve growth factor (NGF) monoclonal antibody (mAb) therapy for cats, designed to alleviate pain associated with osteoarthritis (OA) for up to three months with a single subcutaneous injection. Backed by nearly a decade of science and research, Portela demonstrated effectiveness in alleviating OA pain in a pivotal nine-month European field study with improvements observed from as early as Day 3 after the first injection1.
Portela targets NGF, a recognized mediator of pain and inflammation. By binding to a novel site on NGF, Portela enables up to three months of OA pain relief with a single injection. In clinical trials, Portela was found to...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
